StockData
Tandem Diabetes Care Inc logo

Tandem Diabetes Care Inc (TNDM) stock

TNDMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3030% below fair value
$17.06−1.42 (-7.68%)

Close on Nov 17, 2026Market cap $1.19BP/E –Yield –

Tandem Diabetes Care r&d expenses

Research and development expenses are spending on new products and technology.

Tandem Diabetes Care's R&D Expenses for the twelve months ending Jun 30, 2026 was $187.75M, down 6.9% year over year. For fiscal 2025 it was $193.11M, down 2.9% from the year before. Over ten years it grew 27.5% a year on average. The highest annual figure on record is $198.88M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$193.11M-2.9%
FY2024Dec 31, 2024$198.88M+17.2%
FY2023Dec 31, 2023$169.67M+22.0%
FY2022Dec 31, 2022$139.11M+51.1%
FY2021Dec 31, 2021$92.05M+44.8%
FY2020Dec 31, 2020$63.57M+40.7%
FY2019Dec 31, 2019$45.20M+54.6%
FY2018Dec 31, 2018$29.23M+41.5%
FY2017Dec 31, 2017$20.66M+9.8%
FY2016Dec 31, 2016$18.81M+10.9%
FY2015Dec 31, 2015$16.96M+7.4%
FY2014Dec 31, 2014$15.79M+42.5%
FY2013Dec 31, 2013$11.08M+23.0%
FY2012Dec 31, 2012$9.01M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$46.93M-2.5%
Q1 FY2026Mar 31, 2026$46.04M-8.3%
Q4 FY2025Dec 31, 2025$46.07M-11.8%
Q3 FY2025Sep 30, 2025$48.72M-4.7%
Q2 FY2025Jun 30, 2025$48.12M-2.4%
Q1 FY2025Mar 31, 2025$50.22M+8.6%
Q4 FY2024Dec 31, 2024$52.20M+22.5%
Q3 FY2024Sep 30, 2024$51.11M+21.8%
Q2 FY2024Jun 30, 2024$49.33M+14.9%
Q1 FY2024Mar 31, 2024$46.24M+9.7%
Q4 FY2023Dec 31, 2023$42.60M+19.7%
Q3 FY2023Sep 30, 2023$41.97M+14.1%
Q2 FY2023Jun 30, 2023$42.93M+27.9%
Q1 FY2023Mar 31, 2023$42.16M+27.1%
Q4 FY2022Dec 31, 2022$35.59M+20.7%
Q3 FY2022Sep 30, 2022$36.80M+52.7%
Q2 FY2022Jun 30, 2022$33.57M+63.8%
Q1 FY2022Mar 31, 2022$33.16M+84.6%
Q4 FY2021Dec 31, 2021$29.49M+69.7%
Q3 FY2021Sep 30, 2021$24.10M+49.8%
Q2 FY2021Jun 30, 2021$20.50M+28.2%
Q1 FY2021Mar 31, 2021$17.96M+27.2%
Q4 FY2020Dec 31, 2020$17.38M+38.3%
Q3 FY2020Sep 30, 2020$16.09M+33.7%
Q2 FY2020Jun 30, 2020$15.99M+42.7%
Q1 FY2020Mar 31, 2020$14.12M+50.4%
Q4 FY2019Dec 31, 2019$12.57M+42.9%
Q3 FY2019Sep 30, 2019$12.04M+50.5%
Q2 FY2019Jun 30, 2019$11.20M+73.5%
Q1 FY2019Mar 31, 2019$9.39M+57.1%
Q4 FY2018Dec 31, 2018$8.80M+53.0%
Q3 FY2018Sep 30, 2018$8.00M+62.8%
Q2 FY2018Jun 30, 2018$6.46M+32.7%
Q1 FY2018Mar 31, 2018$5.98M+16.5%
Q4 FY2017Dec 31, 2017$5.75M+32.4%
Q3 FY2017Sep 30, 2017$4.91M-20.1%
Q2 FY2017Jun 30, 2017$4.87M–
Q1 FY2017Mar 31, 2017$5.13M–
Q4 FY2016Dec 31, 2016$4.35M–
Q3 FY2016Sep 30, 2016$6.15M–

More Tandem Diabetes Care figures

See a number that looks wrong?